ANTENA: Artificial Intelligence to render the best clinical trial design for a novel RNA-based therapy for heart failure
Stemming from the collaborative efforts of Summa and HORAIZON, a leading expert in biomedical analytics and AI model generation, we are developing the AI ANTENA platform to support clinical trial enrichment and biomarker verification to identify the best study population for the RNA-based therapies currently developed by Summa. The AI ANTENA platform will be an invaluable tool to help biopharma companies select the best study population from large datasets and will fit seamlessly within the Health and Care application area of the Dutch AI Coalition (NL AIC).
ANTENA is a collaborative project funded by the Netherlands Enterprise Agency under the MIT-R&D-ArtificieĢle intelligentie (AI) 2023 agreement n° MIT-AI-23-03471399.
